RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...
Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...
In this randomized clinical trial that included 338 participants, mean body weight change from baseline to 68 weeks was –15.8% with semaglutide vs –6.4% with liraglutide, a statistically ...
Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...
Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.
This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results